ArticleOpen veterinary journal2025
Successful treatment with recombinant human GH in a kitten with suspected congenital hyposomatotropism.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyposomatotropism is an extremely rare disease in cats. It is associated with stunted growth, and a severely decreased life expectancy is suspected based on the very few cases that have been reported in this species. To date, no treatment has been recommended in cats. Case description: A 4-month-old female British Longhair was presented for stunted growth without any other clinical signs reported. All other causes of growth retardation were excluded, and persistently low circulating insulin growth factor-1 levels were documented, leading to a diagnosis of presumed isolated GH-deficiency. This cat was subcutaneously treated with recombinant human GH (rhGH) for 20 weeks. At the time of treatment discontinuation, the cat had reached the weight of its littermates. No treatment adverse effects were observed. Serum IGF-1 levels were measured 5 months after treatment discontinuation and were within the reference range. Conclusion: This case report describes the successful treatment of a presumed GH-deficient cat with rhGH without adverse effects. rhGH might be a reasonable treatment option in GH-deficient cats, considering the grave prognosis associated with this disease in the few cases described.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.